⚖️ Renpho Morphoscan Base Scale — https://lvnta.com/lv_JdHgSA7agu8wJ8Q3yaThe NHS is about to completely bypass your GP for Mounjaro (Zepbound) + Why I said no to Retatrutide. This is a massive milestone for the Mounjaro UK community. A brand-new £85m pilot is launching across 12 areas, offering direct self-referral access to tirzepatide without a GP appointment. Plus, an FDA warning every GLP-1 user needs to hear — over 1,700 adverse events linked to fake and compounded semaglutide, many resulting in hospitalisation.This week's stories:🏥 NHS bypasses GPs — the £85m OPIP pilot explained🏋️ Jabs, gyms & smartphones — what the pilot actually includes⚠️ FDA fake GLP-1 warning — 1,700+ adverse events reported📊 GPs at breaking point — 1 in 25 consultations now Mounjaro-related

Check out all the update videos on YouTube:👇

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Weekly Videos⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

*The episodes in this series are recorded as YouTube videos; there will be references to things on screen at times if you are listening only.

⚖️ Renpho Morphoscan Base Scale — https://lvnta.com/lv_JdHgSA7agu8wJ8Q3yaThe Morphoscan Base Scale will have deals on Prime Day - A great chance to have one to try!Mounjaro UK (Zepbound) just dominated a real-world head-to-head against Wegovy — and there's a critical muscle loss warning every GLP-1 user needs to hear. This week: tirzepatide vs semaglutide results from 20,000+ patients, new data on the start-and-stop journey, groundbreaking research on GLP-1s rewiring impulsive behaviour, and why your step count matters more than you think.Plus — Father's Day waffle, World Cup chat, and the first ever fully integrated sponsor on the channel.This week's stories:🏆 Tirzepatide vs Semaglutide: Real-world data from 20,000+ patients🔄 The Start & Stop trend — 58% restart within 2 years🧠 GLP-1s and impulsive behaviour: the brain rewiring study⚠️ Physical activity drop & the muscle loss warning

Check out all the update videos on YouTube:👇

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Weekly Videos⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

*The episodes in this series are recorded as YouTube videos; there will be references to things on screen at times if you are listening only.

I made a mistake with this channel — and this week I'm owning up to it. This Mounjaro UK channel is back to what works: honest weekly updates plus the biggest GLP-1 and weight loss news of the week.⚖️ Renpho Smart Scale — https://lvnta.com/lv_JdHgSA7agu8wJ8Q3ya📺 Jane's Channel — https://youtube.com/@Jane50Plus?si=9vlwZ67s1-dXy5J4This week's stories:🔬 RETATRUTIDE — Eli Lilly's Phase 3 results are in. 28.3% average body weight loss. That's not just best-in-class for a GLP-1 — it's entering bariatric surgery territory. This is a massive milestone for the future of obesity treatment.💊 THE ORAL PILL RACE — AstraZeneca's elecoglipron joins orforglipron in the race to become the first once-daily oral weight loss pill. Oral Wegovy has already surpassed 3 million prescriptions. The landscape is shifting fast.💊GLP1 PILLS COMING TO THE UK SOON - Wegovy has been approved in the UK, making it only the 3rd country after the USA and UAE to have access to the pills. No release date or pricing yet, but I will share that as soon as it is available.🎙️ MY PERSONAL UPDATE — Why I sold my Garmin Fenix 8, Whoop, and Oura Ring, and what it says about where my head has been. Plus, what's next for this channel.Whether you're on Mounjaro (Zepbound), tirzepatide, Wegovy, or in maintenance — this is your weekly catch-up.

Check out all the update videos on YouTube:👇

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Weekly Videos⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

*The episodes in this series are recorded as YouTube videos; there will be references to things on screen at times if you are listening only.